Trials / Completed
CompletedNCT05106205
Phamacokinetics and Safety Profiles of DA-5213 10mg in Healthy Subjects
An Open Label, Randomized, Single Dose, Crossover Study to Evaluate the Pharmacokinetics and Safety of DA-5213 10mg in Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- Dong-A ST Co., Ltd. · Industry
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Accepted
Summary
Phamacokinetics and safety profiles of DA-5213 10mg in Healthy subjects
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | DA-5213 10mg | single dose administration (one tablet once a day) |
| DRUG | DA-5213-R 10mg | single dose administration (one tablet once a day) |
Timeline
- Start date
- 2021-12-21
- Primary completion
- 2022-01-20
- Completion
- 2022-01-20
- First posted
- 2021-11-03
- Last updated
- 2022-06-13
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT05106205. Inclusion in this directory is not an endorsement.